Login to Your Account



Repros flexing muscle in testosterone fight: phase III Androxal whups gel, NDA this year

By Randy Osborne
Staff Writer

Thursday, August 28, 2014

Some investor confusion over the results from Repros Therapeutics Inc.'s first of two identical, pivotal phase III trials with Androxal, its oral secondary-hypogonadism treatment, did not stop shares of the company from enjoying an uplift based on the data, which could enable an NDA before 2014 is over.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription